Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
S Redaelli, R Piazza, R Rostagno… - Journal of clinical …, 2008 - europepmc.org
S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega…
Journal of clinical oncology: official journal of the American Society …, 2008•europepmc.orgA comment on this article appears in" Comparative In vitro cellular data alone are insufficient
to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-
resistant chronic myeloid leukemia." J Clin Oncol. 2010 Apr 10; 28 (11): e169-71; author
reply e172.
to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-
resistant chronic myeloid leukemia." J Clin Oncol. 2010 Apr 10; 28 (11): e169-71; author
reply e172.
A comment on this article appears in" Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia." J Clin Oncol. 2010 Apr 10; 28 (11): e169-71; author reply e172.
europepmc.org